Baird Medical Devices Inc., a microwave ablation medical (MWA) device developer and provider headquartered in China and with a U.S. base in Frisco, said it is accelerating its expansion in the United States through senior hires, key partnerships, and capacity building initiatives to support its business.
The company said it experienced rapid momentum in the United States during the fourth quarter of 2023, particularly after receiving the U.S. Food and Drug Administration’s clearance to market its MWA systems and technology in November.
Baird Medical said that Christian Chilcott has been appointed as chief commercial officer, Americas, to drive growth.
Chilcott is a seasoned medical device executive with two decades of industry experience building and operating organizations focused on minimally invasive, interventional procedures in the field of interventional radiology, Baird said.
He brings extensive experience in the areas of soft tissue biopsy, oncology, and the peripheral vasculature. Chilcott is building a team across the U.S. to support business expansion including recent hires in New York, Louisiana, Texas, Florida, and California, the company said.
“I am very excited to join Baird Medical at this critical time,” Chilcott said in a statement. “It is essential that this market understands what makes MWA superior, safe, and the preferred choice of procedure for patients who have access. There is much work to do, but we’re encouraged by the physician and patient feedback so far.”
Focus on thyroid disease treatment
Baird said that since the first procedure was conducted on Jan. 12 by Dr. Alizera Falahati, there has been a steady increase in the number of procedures successfully conducted in the U.S. by leaders in the field of thyroid disease, including Endocrine Surgeon and Director of Robotic Surgery Dr. Rasa Zarnegar of Weill Cornell Medicine and Dr. Raymond Yung, an otolaryngologist and the founder of three specialty clinics in New York City.
Yung practices surgery at NYU Langone Health where he also trains surgical residents. Baird said that advocacy from these physicians offers a strong testament to the preferred procedural approach that MWA offers to both providers and patients alike.
On Feb. 2, Baird Medical said it hosted the North American Society of Interventional Thyroidology (NASIT) Annual Meeting, which welcomed major medical institutions, including Johns Hopkins University School of Medicine, Stanford University Medical Center, Columbia University Medical Center, Tulane University Medical Center, Weill Cornell Medicine, and the NYU School of Medicine to deepen industry best practices and develop high-impact relationships.
Baird said that an important aspect of NASIT was convening medical professionals to offer education on employing the MWA procedure to raise awareness and ensure safety as the technology becomes increasingly available.
‘Take our time to do it well’
Baird said it offers a rigorous medical education program to build industry capacity and safety as a critical part of its business development.
“We are so glad to receive such positive interest and feedback from our partner physicians who hail from both the Unites States and Europe,” Haimei Wu, founder and CEO of Baird Medical, said in a statement. “Entering a mature medical market like the United States requires that we take our time to do it well. This means education and safety is the priority.”
Baird Medical said its proprietary medical devices are used for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung cancer, and breast lumps.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
Michael McMahan follows Kathleen Gibson as CEO, who spent 10 years at the helm of the foundation. McMahan worked for more than a decade at the George W. Bush Presidential Center. He'll now lead the foundation in its mission to build "a sustainable funding source for innovative research, best-in-class medical education, and the highest standard of treatment and care."
-
Five Liters, an offshoot of Spark Biomedical, begins 'first-in-human' trials to explore wearable neurostimulation technology for managing inherited blood disorders and more. Parent Spark Biomedical is focused on its FDA-cleared wearable device for drug-free opioid withdrawal.
-
The Advanced Research Projects Agency for Health—or ARPA-H— wants to enable 90% of eligible Americans to participate in clinical trials within 30 minutes of their homes. The agency officially launched its new Texas "customer experience" headquarters at Dallas' Pegasus Park on Thursday, which will be home base for the initiative.
-
A 2-mile hot zone along the Southwestern Medical District in Dallas is getting a cool makeover. The city's biggest urban heat island is slated to be turned into a dedicated green space. See designs for the corridor, complete with a 10-acre park.
-
A holder of 34 patents, Sherry was a pioneer in designing molecular materials for use in medical imaging. His work on chemicals called macrocyclic ligands led to their use in carrying "a payload of metallic radiotherapeutic compounds that can kill cancer cells on contact, while the outside molecular structure can be designed to bind to a specific protein that ensures precise delivery to only diseased tissue," Amanda Siegfried writes in UT Dallas Magazine.
